The study was a nationwide Phase 3 trial led by UW-Madison surgery professor Dixon Kaufman. The goal was to test a new stem cell infusion treatment for safety and efficacy.
“There are many benefits to them (immunosuppressive drugs),” said Kaufman, the medical director of the UW Health Transplant Center. “But of course, there are side effects and downsides.”